SPOTLIGHT -
COVID-19 Experts Weigh in on Heterologous Booster Doses
The FDA and CDC have authorized and recommended 3 different booster doses, to be used in "mix-and-match" strategy among eligible adults. What does this mean for immunity?
Read More
Flu and Pneumococcal Disease: What Will This Year Bring?
The National Foundation for Infectious Diseases (NFID) recently sponsored a media briefing addressing the risks of contracting influenza and pneumococcal disease in the midst of a still-flourishing COVID-19 pandemic.
Children Capable of Carrying High Levels of Live COVID-19 Virus
Infants, children, and adolescents can carry and spread COVID-19 at the same rate as adults.
National Survey Finds Low Interest in Influenza Vaccination
New survey finds little more than half of US adults are planning to obtain vaccination against influenza despite urging by health officials.
A Review of the Currently Available Monoclonal Antibodies for COVID-19
Outside of vaccines, these underutilized therapies are the best defense against severe disease.
Concomitant COVID-19 and Influenza Vaccination Tested Against Twindemic
New clinical trial is first to describe concomitant administration of any vaccine with either an adenoviral vector or mRNA COVID-19 vaccine.
Time to Prepare People to Accept COVID-19 Endemicity
CYPRESS Trial: RSV Vaccine for Older Adults Elicits Robust Immune Response
The findings have supported the launch of a phase 3 trial called EVERGREEN, which is now underway.
Molnupiravir Could Become the First Authorized COVID-19 Pill
Unpublished, interim phase 3 data show an approximate 50% reduction in hospitalizations and deaths versus placebo. Merck is expediting FDA application for the antiviral drug.
Early 3-Day Remdesivir Regimen Reduces COVID-19 Hospitalization, Death by 87%
The study author of the late-breaking IDWeek findings discusses what the new data mean for using the antiviral to reduce COVID-19 burden.
COVID-19 Breakthrough Infections: How We Got Here
An expert explains the science of vaccine- and infection-induced immunity, and how it informs the timeline of COVID-19 outbreaks this year.
Creating an Influenza Vaccination Campaign for Health Care Workers
A team from a tertiary center in the Middle East used a multidisciplinary approach to increase immunization.
When Delta and Influenza Intersect
With the Delta cases surging in recent weeks, and the upcoming flu season almost upon us, here is a glimpse of what providers and the public can expect when both viruses are circulating.
FDA Authorizes Monoclonal Antibodies for Post-Exposure COVID-19 Prevention
The emergency authorization granted to combination bamlanivimab and etesevimab is the second indicated in this last year.
What to Expect With Influenza in the Era of COVID-19
Here are some insights into this upcoming 2021-2022 influenza season as well as concerns of the twindemic and addressing both the seasonal and pandemic viruses simultaneously.
Novavax Begins Phase 1/2 Study for Its Combination COVID-19 and Influenza Vaccine
The shot will be its NanoFlu/NVX-CoV2373 vaccine using the company’s Matrix-M adjuvant platform.
Flu Shots After Myocardial Infarction May Reduce Cardiovascular Event Risk
Past research has observed links between cardiovascular disease and influenza infection. Vaccination may benefit at-risk patients.
Pfizer Starts Phase 3 Trial for RSV Vaccine
The first participants were vaccinated in the study with Pfizer’s respiratory syncytial virus (RSV) investigational vaccine candidate in adults ages 60 or older.
TB in Persons with HIV in South Africa Increasingly Rifampicin-Resistant
Persons living with HIV are susceptible to TB and also appear at increased risk for infecting strains acquiring rifampicin-resistance.
Pfizer COVID-19 Vaccine Raises Adverse Event Risk, Though Not as Much as COVID-19
An Israel study estimates vaccinated persons' risk of side effects including myocarditis, relative to the risk brought on by SARS-CoV-2 infection.
Will an FDA-Approved COVID-19 Vaccine Convince People to Get the Shot?
David Weber, MD, MPH, explains what portion of the population may buy into the newly approved Pfizer-BioNTech vaccine.
Children, COVID-19, and Another Crazy Respiratory Viral Season
Kevin J. Downes, MD, and Contagion® Section Editor Conan MacDougall, PharmD, MAS, BCPS, BCIDP, discuss these important topics as another season approaches.
FDA Approves Pfizer-BioNTech COVID-19 Vaccine
The full approval for BNT162b2 will afford physicians greater prescribing capability, and will likely drive workplace vaccine mandates.
The Variety of Variants in COVID-19
The evolution of the major variants, including the delta mutation.
US Wants COVID-19 Vaccine Booster Doses at 8 Months
The Biden administration reportedly hopes for FDA-authorized booster doses for the adult general population in the next month.
Still Learning: Optimizing the Diagnosis and Screening of Respiratory Viruses
While the COVID-19 pandemic has helped advance respiratory diagnostics and surveillance, there are still many gaps that remain across the spectrum of healthcare.
How Soon Will COVID-19 Vaccine Booster Doses Be Available in the US?
The US is targeting a possible Fall rollout of publicly available doses, yet experts debate their current necessity.
Experts Weigh in on Booster COVID-19 Vaccine Doses for Immunocompromised Patients
A quartet of infectious disease, vaccinology, and virology experts share thoughts on the FDA's newest emergency authorization for COVID-19 mRNA vaccines.
Delta Means Change
"Humans dislike change, especially when it is rapid, unexpected, or negative. Delta is all 3."
The Unpredictable Factors of the 2021-22 Flu Season
A look at the COVID-19 driven factors for this upcoming influenza season, from reopening classrooms to reduced mutation chances.
